- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03896724
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
A Phase Ib/IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine, R21 Adjuvanted With Matrix-M (R21/MM), in 5-17 Month Old Children in Nanoro, Burkina Faso
Study Overview
Status
Conditions
Detailed Description
In this double-blind, randomised, controlled, phase 2b trial, the low-dose circumsporozoite protein-based vaccine R21, with two different doses of adjuvant Matrix-M (MM), was given to children aged 5-17 months in Nanoro, Burkina Faso-a highly seasonal malaria transmission setting. Three vaccinations were administered at 4-week intervals before the malaria season, with a fourth dose 1 year later. All vaccines were administered intramuscularly into the thigh. Group 1 received 5 μg R21 plus 25 μg MM, group 2 received 5 μg R21 plus 50 μg MM, and group 3, the control group, received rabies vaccinations. Children were randomly assigned (1:1:1) to groups 1-3. An independent statistician generated a random allocation list, using block randomisation with variable block sizes, which was used to assign participants. Participants, their families, and the local study team were all masked to group allocation. Only the pharmacists preparing the vaccine were unmasked to group allocation. Vaccine safety, immunogenicity, and efficacy were evaluated over 1 year. The primary objective assessed protective efficacy of R21 plus MM (R21/MM) from 14 days after the third vaccination to 6 months.
From May 7 to June 13, 2019, 498 children aged 5-17 months were screened, and 48 were excluded. 450 children were enrolled and received at least one vaccination. 150 children were allocated to group 1, 150 children were allocated to group 2, and 150 children were allocated to group 3. The final vaccination of the primary series was administered on Aug 7, 2019. R21/MM had a favourable safety profile and was well tolerated.
Please see publication for more details: Lancet. 2021 May 15;397(10287):1809-1818. doi: 10.1016/S0140-6736(21)00943-0
After the first booster vaccination, participants in Groups 1 and 2 were further randomised 2:1 to receive R21 with Matrix-M: control. The trial was extended by a further two years with yearly boosters of R21/MM or rabies vaccine. Groups 1 and 2 were subdivided and randomized 2:1 to receive R21/MM or rabies vaccine as the second booster. Group 3 received control rabies vaccine as they had done previously. The second boosting occurred between June and July 2021 where 368 participants were boosted. In May 2022 it was decided to amend the protocol to allow for groups 1a and 2a (malaria vaccine groups) to be randomised 1:1 to receive either the R21/Matrix-M vaccine or a control rabies vaccine a year after the previous booster vaccine. The third boosting occurred between June and July 2022 where 357 participants were boosted.
Between June 2, and July 2, 2020, 409 children returned to receive a booster vaccine. Each child received the same vaccination for the booster as they received in the primary series of vaccinations; 132 participants received 5 μg R21 adjuvanted with 25 μg Matrix-M, 137 received 5 μg R21 adjuvanted with 50 μg Matrix-M, and 140 received the control vaccine.
A booster dose of R21/Matrix-M at 1 year following the primary three-dose regimen was administered. The trial is ongoing to assess long-term follow-up of these participants and the value of further booster
Please see publication for more details of results of two year follow up: Lancet Infect Dis. 2022 Dec;22(12):1728-1736. doi: 10.1016/S1473-3099(22)00442-X.
The trial is currently in follow-up and the last volunteer last visit is expected to occur in July 2023.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nanoro, Burkina Faso
- Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy child aged 5-17 months at the time of first study vaccination
- Provide written Informed consent of parent/guardian
- Child and parent/guardian resident in the study area villages and anticipated to be available for vaccination and follow-up for 2 years following last dose of vaccination
Exclusion Criteria:
- Clinically significant skin disorder (psoriasis, contact dermatitis etc.), immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness.
- Weight-for-age Z score of less than -3 or other clinical signs of malnutrition.
- History of allergic reaction, significant IgE-mediated event, or anaphylaxis to immunisation.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g. neomycin.
- Sickle cell disease.
- Clinically significant laboratory abnormality as judged by the study clinician.
- Blood transfusion within one month of enrolment.
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- Previous vaccination with experimental malaria vaccines.
- Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period.
- Current participation in another clinical trial, or within 12 weeks of this study.
- Known maternal HIV infection (No testing will be done by the study team).
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (For corticosteroids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
- Any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
n=150. Age 5-17 month-old. 5mcg R21/25mcg Matrix-M at Day 0, 28 and 56 and 1 year. Following the initial booster, Group 1 will be randomised 2:1 into Groups1a and 1b for 5ug R21/50ug Matrix-M: control. Groups 1a and 1b will receive these second and third booster vaccinations each year prior to the malaria season |
Vaccine
Vaccine
vaccine
|
Experimental: Group 2
n=150. Age 5-17 month-old. 5mcg R21/50mcg Matrix-M at Day 0, 28 and 56 and 1 year. Following the initial booster, Group 2 will be randomised 2:1 into Groups 2a and 2b or 5ug R21/50ug Matrix-M:ccontrol. Groups 2a and 2b will receive these second and third booster vaccinations each year prior to the malaria season |
Vaccine
vaccine
|
Placebo Comparator: Group 3 (control group)
n=150.
Age 5-17 month-old.
Rabies Vaccine by the end of the trial.
|
Vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The protective efficacy (number of cases) against clinical malaria of R21 adjuvanted with Matrix-M in 5-17 month old children living in a malaria-endemic area
Time Frame: for 6 months after the last vaccination
|
We will look for the presence of axillary temperature ≥37.5°C AND P. falciparum parasites density > 5000 asexual forms/µL as a primary case definition of clinical malaria. - We will look for the presence of axillary temperature ≥37.5°C and/ or history of fever within the last 24 hours AND P. falciparum parasites density > 0 for a secondary case definition of clinical malaria. |
for 6 months after the last vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Protective efficacy (number of cases) against clinical malaria
Time Frame: for 12 months after administration of the third dose of vaccine, and for 6 and 12 months after each booster vaccination
|
To assess the protective efficacy (number of cases) against clinical malaria of R21 adjuvanted with Matrix-M in 5-17 months old children living in a malaria-endemic area
|
for 12 months after administration of the third dose of vaccine, and for 6 and 12 months after each booster vaccination
|
Efficacy (number of cases) against asymptomatic P. falciparum infection
Time Frame: at 6 and 12 months after administration of the third dose of vaccine, and for 12 months after each booster vaccination
|
Primary case definition of asymptomatic P. falciparum infection: Presence of axillary temperature < 37.5°C and absence of history of fever within the last 24 hours; AND P. falciparum parasites density > 0 asexual forms/µL
|
at 6 and 12 months after administration of the third dose of vaccine, and for 12 months after each booster vaccination
|
The safety and reactogenicity (number of adverse events) of R21 adjuvanted with Matrix-M in 5-17 month olds living in a malaria-endemic area in the month following each vaccination and at 12 months after administration of the final dose of vaccine
Time Frame: for 6 and 12 months after administration of the third dose of vaccine, and for 12 months after each booster vaccination
|
|
for 6 and 12 months after administration of the third dose of vaccine, and for 12 months after each booster vaccination
|
The humoral immunogenicity (antibody response) of R21 adjuvanted with Matrix-M in 5-17 months old children living in a malaria-endemic area
Time Frame: for 6 and 12 months after administration of the third dose of vaccine, and for 6 months after each booster vaccination
|
|
for 6 and 12 months after administration of the third dose of vaccine, and for 6 months after each booster vaccination
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Objectives: Efficacy (number of cases) against incident cases of severe malaria
Time Frame: 12 months after administration of the final dose of vaccine
|
Primary case definition of severe malaria: Presence of P. falciparum parasites density > 5000 asexuals forms/µL; AND one of more of the following criteria of disease severity:
|
12 months after administration of the final dose of vaccine
|
Exploratory Objectives: Gut microbiome (bacterial communities identified) effect on vaccine response.
Time Frame: for 12 months after administration of the final dose of vaccine
|
• DNA extraction and sequencing to determine differences in gut microbiome between those who respond to vaccination and those who don't.
|
for 12 months after administration of the final dose of vaccine
|
Exploratory Objectives: Genetic testing to elicit differences in vaccine response.
Time Frame: for 12 months after administration of the final dose of vaccine
|
|
for 12 months after administration of the final dose of vaccine
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Datoo MS, Natama HM, Some A, Bellamy D, Traore O, Rouamba T, Tahita MC, Ido NFA, Yameogo P, Valia D, Millogo A, Ouedraogo F, Soma R, Sawadogo S, Sorgho F, Derra K, Rouamba E, Ramos-Lopez F, Cairns M, Provstgaard-Morys S, Aboagye J, Lawrie A, Roberts R, Valea I, Sorgho H, Williams N, Glenn G, Fries L, Reimer J, Ewer KJ, Shaligram U, Hill AVS, Tinto H. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022 Dec;22(12):1728-1736. doi: 10.1016/S1473-3099(22)00442-X. Epub 2022 Sep 7.
- Datoo MS, Natama MH, Some A, Traore O, Rouamba T, Bellamy D, Yameogo P, Valia D, Tegneri M, Ouedraogo F, Soma R, Sawadogo S, Sorgho F, Derra K, Rouamba E, Orindi B, Ramos Lopez F, Flaxman A, Cappuccini F, Kailath R, Elias S, Mukhopadhyay E, Noe A, Cairns M, Lawrie A, Roberts R, Valea I, Sorgho H, Williams N, Glenn G, Fries L, Reimer J, Ewer KJ, Shaligram U, Hill AVS, Tinto H. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021 May 15;397(10287):1809-1818. doi: 10.1016/S0140-6736(21)00943-0. Epub 2021 May 5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAC076
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria,Falciparum
-
University of OxfordTerminatedP. Falciparum MalariaThailand
-
National Institute of Allergy and Infectious Diseases...CompletedAccute Falciparum MalariaMali
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...CompletedAzithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in BangladeshUncomplicated Falciparum MalariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...UnknownUncomplicated Falciparum MalariaMyanmar
-
University of OxfordNanyang Technological University; Texas Biomedical Research InstituteCompletedP. Falciparum Malaria | P. Falciparum Malaria Mixed InfectionThailand
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Novartis PharmaceuticalsRecruitingUncomplicated Plasmodium Falciparum MalariaCôte D'Ivoire, Kenya, Ghana, Uganda
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Department of Medical Research...WithdrawnUncomplicated Falciparum Malaria | Artemisinin-resistant
-
Novartis PharmaceuticalsCompletedAcute Uncomplicated P. Falciparum Malaria
Clinical Trials on R21 adjuvanted with 25mcg Matrix-M
-
University of OxfordCompleted
-
University of OxfordBill and Melinda Gates Foundation; University Hospitals Bristol and Weston...RecruitingMalaria,FalciparumUnited Kingdom
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical...RecruitingMalaria, Plasmodium FalciparumGambia
-
University of OxfordMRC/UVRI and LSHTM Uganda Research UnitRecruiting
-
University of OxfordLondon School of Hygiene and Tropical Medicine; KEMRI-Wellcome Trust Collaborative... and other collaboratorsActive, not recruiting
-
University of OxfordCompletedSafety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults (R21/Matrix-M)Malaria,FalciparumThailand
-
University of OxfordCompleted
-
University of OxfordRecruitingMalaria,FalciparumBurkina Faso
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Kenya...Completed
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Kenya...Recruiting